AKIR001

About Akiram Therapeutics

Akiram Therapeutics is a Stockholm-based biotech founded in 2022, advancing a targeted radioimmunotherapy platform for metastatic solid cancers. The company's lead candidate, AKIR001, is already in Phase I clinical trials, with promising preclinical data featured in leading journals. Akiram combines expertise in radiation sciences, oncology, and drug development to create first-in-class radiopharmaceuticals for patients with limited treatment options. The company is privately held, pre-revenue, and actively seeking investment and partnerships to advance its clinical programs.

Therapeutic Areas